EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSMFAG00000031598
Gene Symbol: DHCR24
2 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSMFAG00000036118
Gene Symbol: HMGCR
4 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSMFAG00000046346
Gene Symbol: HPD
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S11-Like

Ensembl ID : ENSMFAG00000007648
Gene Symbol: LOC102129434
2 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S12-Like

Ensembl ID : ENSMFAG00000042652
Gene Symbol: LOC102126208
3 Cross references
154 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S15a

Ensembl ID : ENSMFAG00000039736
Gene Symbol: LOC102130617
2 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S3a-Like

Ensembl ID : ENSMFAG00000048501
Gene Symbol: LOC102123730
3 Cross references
150 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5'-Nucleotidase Ecto

Ensembl ID : ENSMFAG00000033027
Gene Symbol: NT5E
4 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMFAG00000042700
Gene Symbol: HTR1B
4 Cross references
245 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1d

Ensembl ID : ENSMFAG00000029390
Gene Symbol: HTR1D
4 Cross references
60 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSMFAG00000030866
Gene Symbol: HTR1E
4 Cross references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMFAG00000060544
Gene Symbol: HTR2A
2 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).